# Clinical Profile and Admission Outcomes of Patients With Acute Pulmonary Embolism at a Resource‐Constrained Hospital in Ghana: A Retrospective Pilot Study

**Authors:** Prosper Adjei, Samuel Kyeremeh Adjei, Kingsley Owusu Manu

PMC · DOI: 10.1002/hsr2.71951 · Health Science Reports · 2026-03-02

## TL;DR

This study examines the clinical features and outcomes of acute pulmonary embolism patients in a Ghanaian hospital, finding a high in-hospital mortality rate and underuse of pretest probability assessments.

## Contribution

The study provides the first clinical insights into acute pulmonary embolism in a resource-constrained setting in Ghana.

## Key findings

- The majority of patients had intermediate-risk pulmonary embolism, with a notable in-hospital mortality rate of 11.8%.
- Pretest probability assessment was infrequently performed, indicating a potential gap in clinical practice.
- Common risk factors included age over 65, immobilization, obesity, and recent surgery.

## Abstract

Pulmonary embolism is a cardiovascular disease associated with significant morbidity and mortality. There is a paucity of literature regarding this condition from the Ghanaian perspective. This study aimed at evaluating the clinical profile and admission outcomes of patients with acute pulmonary embolism at the Methodist Hospital, Wenchi, Ghana.

A retrospective pilot study was conducted by analyzing medical records of patients diagnosed with acute pulmonary embolism from September 2023 to March 2025. Data on demographics, clinical manifestations, risk factors, investigations, treatment, and outcomes of admission were collected.

Out of 17 patients enrolled in the study, 11 (64.7%) were females. The mean age was 58.8 ± 13.0 years. The commonest risk factors were age > 65 years (n = 6), immobilization (n = 5), obesity (n = 4), and recent surgery (n = 3). Hypertension and diabetes mellitus were the predominant comorbidities. Dyspnea (76.5%, n = 13) and chest pain (n = 5) were the most frequent presenting symptoms while tachypnea (70.6%, n = 12), tachycardia (70.6%, n = 12), and hypoxia (52.9%, n = 9) were the commonest clinical signs. Three patients had hemodynamic instability. Pretest probability assessment was infrequently performed (n = 7). Sinus tachycardia (76.5%, n = 13) was the predominant electrocardiographic abnormality. The majority (58.8%, n = 10) had intermediate‐risk pulmonary embolism whereas 3 patients were classified as having high‐risk pulmonary embolism. Two in‐hospital mortalities were recorded.

Clinical features and predisposing factors were largely similar to those described in the literature. Also, pretest probability assessment was underutilized. In‐hospital mortality rate (11.8%) was relatively high. Large‐scale, multicenter prospective studies are recommended to assess long‐term complications of acute pulmonary embolism such as recurrence and chronic thromboembolic pulmonary hypertension.

## Linked entities

- **Diseases:** pulmonary embolism (MONDO:0005279), diabetes mellitus (MONDO:0005015), chronic thromboembolic pulmonary hypertension (MONDO:0013024)

## Full-text entities

- **Genes:** FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}
- **Diseases:** sPESI (MESH:D045169), sepsis (MESH:D018805), infectious diseases (MESH:D003141), Sinus tachycardia (MESH:D013616), tenderness (MESH:D063806), thromboembolic occlusion (MESH:D013923), myocardial infarction (MESH:D009203), right ventricular dysfunction (MESH:D018497), cardiovascular death (MESH:D002318), hypovolemia (MESH:D020896), Tachypnea (MESH:D059246), lower extremity (MESH:D010291), DVT (MESH:D020246), cough (MESH:D003371), thrombus (MESH:D013927), Hypertension (MESH:D006973), VTE (MESH:D054556), death (MESH:D003643), acute (MESH:D000208), thrombotic pulmonary emboli (MESH:D020766), Acute Pulmonary Embolism (MESH:D011655), cor pulmonale (MESH:D011660), Hypoxia (MESH:D000860), arrhythmia (MESH:D001145), Tachycardia (MESH:D013610), obesity (MESH:D009765), respiratory disorders (MESH:D012131), pleural effusion (MESH:D010996), stroke (MESH:D020521), hemoptysis (MESH:D006469), chest pain (MESH:D002637), fatigue (MESH:D005221), COPD (MESH:D029424), diabetes mellitus (MESH:D003920), right ventricular failure (MESH:D051437), Dyspnea (MESH:D004417), swelling (MESH:D004487), acute thrombosis (MESH:D065666), hyperglycemia (MESH:D006943), syncope (MESH:D013575), circulatory collapse (MESH:D012769), CUS (MESH:D009408), calf pain (MESH:D010146), pulmonary infarction (MESH:D054060)
- **Chemicals:** heparin (MESH:D006493), warfarin (MESH:D014859), serotonin (MESH:D012701), low-molecular-weight heparin (MESH:D006495), rivaroxaban (MESH:D000069552), CTPA (-), dobutamine (MESH:D004280), norepinephrine (MESH:D009638), enoxaparin (MESH:D017984), fondaparinux (MESH:D000077425), thromboxane A2 (MESH:D013928), oxygen (MESH:D010100)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953721/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953721/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953721/full.md

---
Source: https://tomesphere.com/paper/PMC12953721